Stockreport

SpringWorks Therapeutics Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN

SpringWorks Therapeutics, Inc. - common stock  (SWTX) 
Last springworks therapeutics, inc. - common stock earnings: 3/12 04:30 pm Check Earnings Report
PDF STAMFORD, Conn., March 04, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare [Read more]